Clinical Trials

518 enrolled

Urinary Bladder Neoplasms

NCT05294172 2026-05-08

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

295 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT05347134 2026-05-08

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

254 enrolled

Triple Negative Breast Neoplasms

NCT06081959 2026-05-08

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

376 enrolled

Breast Neoplasms

NCT06211764 2026-05-08

SunRISe-5

272 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06319820 2026-05-08

MoonRISe-1

641 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06608927 2026-05-08

PRISM-1

610 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06632327 2026-05-08

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

1,100 enrolled

Lung Neoplasms

NCT06919965 2026-05-08

MoonRISe-3

220 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05171647 2026-05-07

SUNMO

Phase 3 Not yet recruiting

208 enrolled 12 charts

Lymphoid

Lymphoma, Non-Hodgkin

NCT07570823 2026-05-06

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

101 enrolled

Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT03456076 2026-05-05

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

257 enrolled 14 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05104866 2026-05-05

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

732 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT05538663 2026-05-05

BRIDGE

870 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT02446600 2026-05-04

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

579 enrolled 17 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03775265 2026-05-04

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

475 enrolled

Urinary Bladder Neoplasms

NCT06958328 2026-05-04

LAP100

356 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT07097142 2026-05-04

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

486 enrolled

Phase 3 Not yet recruiting

Urinary Bladder Neoplasms

NCT07564141 2026-05-04

RAINFOL™-07

688 enrolled

Gynecologic

Ovarian Neoplasms

NCT02542293 2026-05-01

NEPTUNE

953 enrolled 29 charts

Non Small Cell Lung Carcinoma NSCLC

NCT04241185 2026-05-01

MK-3475-992

520 enrolled

Urinary Bladder Neoplasms

NCT02486718 2026-04-30

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

1,280 enrolled 24 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT06103864 2026-04-30

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

625 enrolled